These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2809279)

  • 21. Induction of class I major histocompatibility complex antigens in human teratocarcinoma cells by interferon without induction of differentiation, growth inhibition, or resistance to viral infection.
    Andrews PW; Trinchieri G; Perussia B; Baglioni C
    Cancer Res; 1987 Feb; 47(3):740-6. PubMed ID: 3026615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation of Hybridomas producing monoclonal antibodies against human interferon.
    Andzhaparidze OG; Nagieva FG; Pille ER; Nikulina VG; Barkova EP; Etkind GV; Melnikova NL; Khats YuS ; Sidorova EV
    Acta Virol; 1988 Nov; 32(6):481-6. PubMed ID: 2906219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects.
    Naldini A; Fleischmann WR
    J Biol Response Mod; 1987 Oct; 6(5):546-55. PubMed ID: 3119781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon entry through the blood-brain barrier in glioma and its effect on lipoxygenase activity.
    Wiranowska M; Prockop LD; Naidu AK; Saporta S; Kori S; Kulkarni AP
    Anticancer Res; 1994; 14(3A):1121-6. PubMed ID: 7521151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta.
    Ratliff TL; Kadmon D; Shapiro A; Jacobs AJ; Heston WD
    Cancer Res; 1984 Oct; 44(10):4377-81. PubMed ID: 6432311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon.
    Le J; Prensky W; Yip YK; Chang Z; Hoffman T; Stevenson HC; Balazs I; Sadlik JR; Vilcek J
    J Immunol; 1983 Dec; 131(6):2821-6. PubMed ID: 6417232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunologic differentiation between E. coli and CHO cell-derived recombinant and natural human beta-interferons.
    Colby CB; Inoue M; Thompson M; Tan YH
    J Immunol; 1984 Dec; 133(6):3091-5. PubMed ID: 6386981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages.
    Ling PD; Warren MK; Vogel SN
    J Immunol; 1985 Sep; 135(3):1857-63. PubMed ID: 3926890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.
    Handa K; Suzuki R; Matsui H; Shimizu Y; Kumagai K
    J Immunol; 1983 Feb; 130(2):988-92. PubMed ID: 6294182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
    Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor.
    Eppstein DA; Marsh YV; van der Pas M; Felgner PL; Schreiber AB
    Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3688-92. PubMed ID: 3159018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-alpha antibodies in autoimmune diseases.
    Prümmer O; Seyfarth C; Scherbaum WA; Drees N; Porzsolt F
    J Interferon Res; 1989 Sep; 9 Suppl 1():S67-74. PubMed ID: 2681443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of recombinant murine interferon beta against mouse hepatitis virus infection.
    Minagawa H; Takenaka A; Mohri S; Mori R
    Antiviral Res; 1987 Sep; 8(2):85-95. PubMed ID: 2830846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
    J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients.
    Dummer R; Müller W; Nestle F; Wiede J; Dues J; Lechner W; Haubitz I; Wolf W; Bill E; Burg G
    Cancer; 1991 May; 67(9):2300-4. PubMed ID: 1901514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large-scale, one-step purification of murine interferon-beta using a monoclonal antibody.
    Vonk WP; Trapman J
    J Interferon Res; 1983; 3(2):169-75. PubMed ID: 6875311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two monoclonal antibodies distinguish between human recombinant interferon-alpha 5s produced by Escherichia coli and by mouse cells.
    Tsukui K; Fukunaga R; Nagata S; Ito K
    Microbiol Immunol; 1986; 30(12):1271-9. PubMed ID: 2437432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of mouse interferon-beta in normal and brain tumour-bearing mice.
    Mihara Y; Kuratsu J; Takaki S; Hori K; Nagai E; Satoh Y; Minowa N; Ushio Y
    Acta Neurochir (Wien); 1991; 109(1-2):46-51. PubMed ID: 2068966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect of recombinant murine interferon-beta against mouse malignant glioma.
    Kuroki M; Tanaka R; Suzuki Y; Moriyama M; Kuwabara Y; Kobayashi S
    J Interferon Res; 1987 Jun; 7(3):301-11. PubMed ID: 3497213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purification and characterization of recombinant mouse interferon-beta.
    Matsuda S; Utsumi J; Kawano G
    J Interferon Res; 1986 Oct; 6(5):519-26. PubMed ID: 3543158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.